Diagnostic and interventional imaging · 2026
Quantitative CT biomarkers for predicting clinical outcomes after prostatic artery embolization: Results of the prospective pilot EMBOPERF study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sammoud Skander, Dabli Djamel, De Oliveira Fabien, Serrand Chris, Segui Paul, Kammoun Tarek, Jelloun Ghizlane Touimi Ben, Loukil Houssem, Zoppardo Adrien, Pastor Maxime, Greffier Joël, Longueville Florence, Beregi Jean-Paul, Droupy Stéphane, Frandon Julien
Аннотация
PURPOSE: The purpose of this study was to prospectively evaluate whether quantitative variables obtained using computed tomography (CT) perfusion and dual-energy CT (DECT) can predict 3-month clinical success after prostatic artery embolization (PAE) in patients with benign prostatic hyperplasia (BPH).
MATERIALS AND METHODS: Thirty-eight men (mean age, 74.1 ± 9.2 [standard deviation (SD)] years; mean prostate volume, 107.7 ± 45.1 [SD] mL) with symptomatic BPH underwent CT perfusion and DECT (venous phase at 80 s; delayed phase at 3 min) before PAE. Quantitative variables included the perfusion integrated total enhancement (ITE), delayed-phase iodine charge, and venous-to-delayed iodine charge ratio. Clinical success was defined as the removal of an indwelling catheter or a reduction of at least 25 % in the International Prostate Symptom Score (IPSS) and/or an improvement of at least one point in quality of life (QoL) after three months. Statistical analyses included group comparisons, receiver-operating characteristic (ROC) analysis, and targeted multivariable logistic regression analysis.
RESULTS: Clinical success was achieved in 31/38 patients (82 %). Patients with successful PAE had a significantly greater ITE (0.117 ± 0.175 [SD]) and a higher venous-to-delayed iodine charge ratio (0.886 ± 0.138 [SD]) than those with failed PAE (0.051 ± 0.020 [SD], and 0.650 ± 0.096 [SD], respectively; P = 0.018 and P < 0.001, respectively. Venous-to-delayed iodine charge ratio yielded 81 % sensitivity (95 % confidence interval [CI]: 62-93), 100 % specificity (95 % CI: 59-100) and an area under the ROC curve (AUC) of 0.931 (95 % CI: 0.850-1.000) to predict clinical success of PAE. In multivariable analysis, the venous-to-delayed iodine charge ratio remained an independent predictor of PAE success (P = 0.030).
CONCLUSION: The CT-derived venous-to-delayed iodine charge ratio is a promising noninvasive biomarker for predicting clinical success after PAE in patients with BPH. These findings could improve patient selection and personalize BPH management.
MATERIALS AND METHODS: Thirty-eight men (mean age, 74.1 ± 9.2 [standard deviation (SD)] years; mean prostate volume, 107.7 ± 45.1 [SD] mL) with symptomatic BPH underwent CT perfusion and DECT (venous phase at 80 s; delayed phase at 3 min) before PAE. Quantitative variables included the perfusion integrated total enhancement (ITE), delayed-phase iodine charge, and venous-to-delayed iodine charge ratio. Clinical success was defined as the removal of an indwelling catheter or a reduction of at least 25 % in the International Prostate Symptom Score (IPSS) and/or an improvement of at least one point in quality of life (QoL) after three months. Statistical analyses included group comparisons, receiver-operating characteristic (ROC) analysis, and targeted multivariable logistic regression analysis.
RESULTS: Clinical success was achieved in 31/38 patients (82 %). Patients with successful PAE had a significantly greater ITE (0.117 ± 0.175 [SD]) and a higher venous-to-delayed iodine charge ratio (0.886 ± 0.138 [SD]) than those with failed PAE (0.051 ± 0.020 [SD], and 0.650 ± 0.096 [SD], respectively; P = 0.018 and P < 0.001, respectively. Venous-to-delayed iodine charge ratio yielded 81 % sensitivity (95 % confidence interval [CI]: 62-93), 100 % specificity (95 % CI: 59-100) and an area under the ROC curve (AUC) of 0.931 (95 % CI: 0.850-1.000) to predict clinical success of PAE. In multivariable analysis, the venous-to-delayed iodine charge ratio remained an independent predictor of PAE success (P = 0.030).
CONCLUSION: The CT-derived venous-to-delayed iodine charge ratio is a promising noninvasive biomarker for predicting clinical success after PAE in patients with BPH. These findings could improve patient selection and personalize BPH management.